- Rating Decision dated February 25, 2021
- Higher Level Review Informal Conference dated February 25, 2021
- VA Form 20-0999 Higher-Level Review Return dated February 25, 2021
- Georgia Cancer Specialists Medical Treatment Record received on March 22, 2021
- Hematologic and Lymphatic Conditions Disability Benefits Questionnaire with Medical Opinion dated May 06, 2021 from contractor QTC received on June 02, 2021

REASONS FOR DECISION

Service connection for myeloproliferative disorder (also claimed as polycythemia and thrombocythemia).

Service connection for myeloproliferative disorder (also claimed as polycythemia and thrombocythemia) has been established as directly related to military service. (38 CFR 3.303, 38 CFR 3.304)

An evaluation of 30 percent is assigned from May 28, 2019, the date we received your intent to file and you have continuously pursued your claim. (38 CFR 3.400, 38 CFR 3.2500, 38 CFR3.155)

We have assigned a 30 percent evaluation for your myeloproliferative disorder (also claimed as polycythemia and thrombocythemia) based on:
• Requiring phlebotomy 4-5 times per 12-month period

A higher evaluation of 60 percent is not warranted for polycythemia vera unless the evidence shows:
• Requiring molecularly targeted therapy for the purpose of controlling RBC count; or,
• Requiring phlebotomy 6 or more times per 12-month period for the purpose of controlling RBC count. (38 CFR 4.117)

REFERENCES:

Title 38 of the Code of Federal Regulations, Pensions, Bonuses and Veterans' Relief contains the regulations of the Department of Veterans Affairs which govern entitlement to all Veteran benefits. For additional information regarding applicable laws and regulations, please consult your local library, or visit us at our website, www.va.gov.